Trials / Terminated
TerminatedNCT03348163
(mo)BETTA Trial in Transwomen for Optimization of ART
Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B/FTC/TAF | B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen) |
| DRUG | Current ART | Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent. |
Timeline
- Start date
- 2018-06-06
- Primary completion
- 2020-12-15
- Completion
- 2020-12-15
- First posted
- 2017-11-20
- Last updated
- 2022-10-03
- Results posted
- 2022-10-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03348163. Inclusion in this directory is not an endorsement.